33494-81-4Relevant articles and documents
A extractant composition and its preparation method and application
-
Paragraph 0092; 0093, (2018/11/22)
The invention discloses an extractant composition as well as a preparation method and an application thereof. The composition comprises the following components in percentages by weight: a component A: 80-99.99wt% of dialkyl phosphinic acid with a structure shown in a formula I; a component B: 0-5wt% of dialkyl phosphinic acid with a structure shown in a formula II; a component C: 0-5wt% of dialkyl phosphinic acid alkyl ester with a structure shown in a formula III; a component D: 0-10wt% of alkyl phosphorous acid mono alkyl ester with a structure shown in a formula IV; wherein, the component B, C and D are not zero at the same time, and the sum of the component A, B, C and D is always 100wt%. The extractant composition containing synergistic extractant components is prepared, the composition is used as an extractant and can be widely applied to rare earth metals, especially separation and purification of cobalt nickel bimetals, and compared with monocomponent extraction agents, the composition has more excellent extraction performance; compared with bis (2,4,4-trimethylpentyl)-phosphinic acid, other synergistic extractant components are easy to synthesize, and production cost of the product is reduced.
Novel triclabendazole prodrug: A highly water soluble alternative for the treatment of fasciolosis
Flores-Ramos, Miguel,Ibarra-Velarde, Froylán,Jung-Cook, Helgi,Hernández-Campos, Alicia,Vera-Montenegro, Yolanda,Castillo, Rafael
supporting information, p. 616 - 619 (2017/01/17)
In this work we present the synthesis, aqueous solubility and stability, hydrolysis by alkaline phosphatase, and in vivo fasciolicidal activity in sheep of a highly water soluble phosphate salt prodrug of triclabendazole (MFR-5). The aqueous solubility of MFR-5 at pH 7 was 88,000-fold that of triclabendazole. MFR-5 showed excellent aqueous stability (>95% after 26?h) at pH 7, making it ideal for developing pharmaceutical compositions in the form of solutions that can easily be hydrolyzed by the enzyme alkaline phosphatase (t?=?13.6?s) to liberate the precursor compound. An aqueous solution of MFR-5 administered intramuscularly to sheep at concentrations of 4, 6 and 8?mg/kg presented a fasciolicidal efficiency of 96.5%, 98.4% and 99.2%, respectively. In the in vivo experiments, MFR-5 reduced 100% the excretion of eggs in all of the above concentrations.
METHODS OF BLADDER CANCER TREATMENT WITH CICLOPIROX, CICLOPIROX OLAMINE, OR A CICLOPIROX PRODRUG
-
Paragraph 095, (2016/06/06)
A method of treating bladder cancer is provided. The method of treating bladder cancer can include: providing a pharmaceutical composition having ciclopirox or ciclopirox olamine or a ciclopirox-POM prodrug having a structure of one of the formulae provided herein or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof; and administering the pharmaceutical composition to a subject having the bladder cancer. The ciclopirox or ciclopirox olamine or a ciclopirox-POM prodrug can be administered in a therapeutically effective amount.